Back to top
more

BioNTech (BNTX)

(Real Time Quote from BATS)

$110.04 USD

110.04
568,523

-1.03 (-0.93%)

Updated Aug 6, 2025 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?

by Zacks Equity Research

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.

Zacks Equity Research

Pfizer (PFE) Seems Well-Poised for Long-Term Growth: Here's How

by Zacks Equity Research

Though Pfizer's (PFE) revenues from COVID products are declining sharply, it is set to launch some key non-COVID products in 2023, which can drive long-term sales and profit growth.

Zacks Equity Research

Pfizer's (PFE) Q2 Earnings Beat, Sales Miss, Stock Declines

by Zacks Equity Research

Pfizer (PFE) beats estimates for second-quarter earnings but misses the same for sales. It trims the upper end of its revenue guidance range for 2023. Stock falls.

Zacks Equity Research

How Will Pfizer's (PFE) Key Drugs Perform in Q2 Earnings?

by Zacks Equity Research

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.

Zacks Equity Research

Pfizer (PFE) to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.

Zacks Equity Research

Should Value Investors Buy BioNTech (BNTX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

How Much Upside is Left in BioNTech SE Sponsored ADR (BNTX)? Wall Street Analysts Think 40.69%

by Zacks Equity Research

The mean of analysts' price targets for BioNTech SE Sponsored ADR (BNTX) points to a 40.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug

by Zacks Equity Research

Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.

Zacks Equity Research

New Strong Buy Stocks for July 11th

by Zacks Equity Research

BLBD, BNTX, EC, TIMB and HIVE have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2023.

Zacks Equity Research

Novavax's (NVAX) COVID Jab Gets Full Approval in Europe

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.

Zacks Equity Research

Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab

by Zacks Equity Research

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.

Zacks Equity Research

Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.

Zacks Equity Research

Implied Volatility Surging for BioNTech (BNTX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

Zacks Equity Research

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

by Zacks Equity Research

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

Zacks Equity Research

BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody

by Zacks Equity Research

BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.

Zacks Equity Research

EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

Zacks Equity Research

Are Options Traders Betting on a Big Move in BioNTech (BNTX) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

Zacks Equity Research

Will Pfizer (PFE) Beat Expectations This Earnings Season?

by Zacks Equity Research

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q1.

Sundeep Ganoria headshot

FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations

by Sundeep Ganoria

To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.

Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $124.57, marking a +1.63% move from the previous day.

Zacks Equity Research

Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day.

Andrew Rocco headshot

Bear of the Day: BioNTech (BNTX)

by Andrew Rocco

BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.

Zacks Equity Research

Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $132.08, marking a +1.88% move from the previous day.